Beike Biotechnology and Tsinghua University’s Shenzhen Graduate School have established a laboratory for cell reprogramming and gene engineering studies. The 1,200-square-meter facility, will mark China’s entry into the race to find new stem cell therapies, the collaborators point out.
The lab will be used to conduct research on stem cells, the nuclear transfer and reprogramming of cells, mAbs, and other cell-engineering innovations. The partners anticipate that $4 million will be spent purely on equipment. This money is part of a $12 million grant from the Shenzhen Municipal Government given out in 2007 to encourage innovative technologies in the area. Additional awards from the government will help cover the cost of running the lab and any future expansion.
“We are already helping thousands of patients with our current umbilical cord stem cell treatments, but this ultrahigh-tech lab will bring us even closer to our goal of helping millions of patients improve their quality of life and will ensure that we have more advanced products in our pipeline four to five years out,” remarks Sean Hu, Ph.D., chairman of Beike Biotech.